#United States #California #Pomerantz LLP #Nektar Therapeutics #NKTR

Recent Lawsuit Filed Against Nektar Therapeutics

In an important development, Pomerantz LLP has filed a class action lawsuit against Nektar Therapeutics, Inc., a prominent biopharmaceutical company, along with certain of its appointed officers. This lawsuit is in response to accusations of violations of federal securities laws during the specified Class Period from February 26, 2025, to December 15, 2025. The filing was made in the United States District Court for the Northern District of California, under case number 26-cv-01951.

This class action lawsuit represents all individuals and entities, excluding the defendants, who purchased or acquired Nektar securities during the aforementioned period. The aim is to recover damages resulting from the alleged misconduct by the company and its top executives, primarily focused on the integrity of their drug trial conduct.

Background of Nektar Therapeutics

Nektar Therapeutics is a biopharmaceutical entity keen on innovation, particularly in developing therapies that modulate the immune system. The company's flagship candidate, rezpegaldesleukin (or REZPEG), is particularly designed as a treatment for autoimmune disorders, such as alopecia areata. Nektar commenced the Phase 2b REZOLVE-AA trial in March 2024, aiming to evaluate the efficacy of REZPEG on patients afflicted by severe alopecia areata. The trial aimed to take a considerably rigorous approach in selecting eligible patients, ensuring that only those who had not undergone previous treatments would participate.

The Allegations

Throughout the Class Period, the Plaintiffs allege that the company and its executives made materially false and misleading statements. Particularly, the Complaint claims that Nektar's enrollment protocols in the REZOLVE-AA trial deviated from the established standards and guidelines. This led to serious implications regarding the reliability of trial results, which the company falsely portrayed as positive and equally met the required criteria for enrollment.

As the pivotal date of December 16, 2025, approached, Nektar published a press release that reported the trial's topline results, revealing a failure to reach statistical significance. This disclosure served as a turning point, leading to a significant decline in Nektar's stock value, a drop of 7.77%, reflecting concerns regarding the validity of their clinical trials.

Seeking Justice

The firm urges investors who acquired Nektar securities within the classified dates to reach out if they're interested in being appointed as Lead Plaintiff. Interested parties have until May 5, 2026, to participate, and the complete complaint can be accessed on Pomerantz's official website. Legal representatives are available for consultation via phone or email for inquiries from potential claimants.

Pomerantz LLP: Advocating for Investors

Pomerantz LLP, based in New York with additional offices across major cities, has long been recognized as a leading practice in corporate, securities, and antitrust class litigation. The firm holds a rich history dating back over 85 years in protecting investors from securities fraud, offering a solid foundation for those impacted by alleged corporate misconduct. Their commitment to ensuring corporate accountability continues to drive their efforts in such class actions.

For those affected, the message is clear: seeking legal recourse not only works towards personal compensation but also preserves trust and integrity in financial markets. As classes against corporations gain traction, the vigilant efforts of firms like Pomerantz are pivotal for affected investors.

For more details, you may reach out to Danielle Peyton at Pomerantz LLP using the provided contact details. Their legal team stands ready to assist and navigate prospective plaintiffs through this challenging process.